S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
S&P 500   3,666.72 (-0.06%)
DOW   29,969.52 (+0.29%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.10%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
Log in
NASDAQ:PIRS

Pieris Pharmaceuticals Stock Forecast, Price & News

$2.94
+0.05 (+1.73 %)
(As of 12/3/2020 04:30 PM ET)
Add
Compare
Today's Range
$2.85
Now: $2.94▼
$2.98
50-Day Range
$2.16
MA: $2.60▼
$2.95
52-Week Range
$1.60
Now: $2.94▼
$4.30
Volume261,233 shs
Average Volume450,557 shs
Market Capitalization$164.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.33
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc.; and license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a research collaboration with the laboratories of University of Pittsburgh. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Pieris Pharmaceuticals logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.55 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PIRS
Previous Symbol
CUSIPN/A
CIK1583648
Webwww.pieris.com
Phone857-246-8998
Employees114

Debt

Debt-to-Equity RatioN/A
Current Ratio5.04
Quick Ratio5.04

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$46.28 million
Price / Sales3.56
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.93 per share
Price / Book3.16

Profitability

EPS (Most Recent Fiscal Year)($0.56)
Net Income$-25,470,000.00
Net Margins-25.90%
Return on Equity-35.00%
Return on Assets-11.81%

Miscellaneous

Outstanding Shares55,971,000
Market Cap$164.55 million
Next Earnings Date3/12/2021 (Estimated)
OptionableOptionable
$2.94
+0.05 (+1.73 %)
(As of 12/3/2020 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PIRS News and Ratings via Email

Sign-up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions

How has Pieris Pharmaceuticals' stock price been impacted by Coronavirus?

Pieris Pharmaceuticals' stock was trading at $2.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PIRS shares have increased by 31.8% and is now trading at $2.94.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Pieris Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Pieris Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Pieris Pharmaceuticals?

Wall Street analysts have given Pieris Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pieris Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Pieris Pharmaceuticals' next earnings date?

Pieris Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Pieris Pharmaceuticals.

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) released its quarterly earnings data on Wednesday, November, 4th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.13. Pieris Pharmaceuticals had a negative return on equity of 35.00% and a negative net margin of 25.90%.
View Pieris Pharmaceuticals' earnings history.

What price target have analysts set for PIRS?

3 brokerages have issued 1 year price targets for Pieris Pharmaceuticals' stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate Pieris Pharmaceuticals' share price to reach $7.00 in the next year. This suggests a possible upside of 138.1% from the stock's current price.
View analysts' price targets for Pieris Pharmaceuticals.

Are investors shorting Pieris Pharmaceuticals?

Pieris Pharmaceuticals saw a increase in short interest in October. As of October 30th, there was short interest totaling 2,200,000 shares, an increase of 26.4% from the October 15th total of 1,740,000 shares. Based on an average daily trading volume, of 403,800 shares, the days-to-cover ratio is currently 5.4 days.
View Pieris Pharmaceuticals' Short Interest.

Who are some of Pieris Pharmaceuticals' key competitors?

Some companies that are related to Pieris Pharmaceuticals include Starpharma (SPHRY), Luna Innovations (LUNA), Anavex Life Sciences (AVXL), Auxly Cannabis Group (CBWTF), Eloxx Pharmaceuticals (ELOX), Eloxx Pharmaceuticals (ELOX), Bioanalytical Systems (BASI), Cleveland BioLabs (CBLI), NanoViricides (NNVC), NanoViricides (NNVC), ProMIS Neurosciences (ARFXF), AIkido Pharma (AIKI), Inhibitor Therapeutics (INTI), HedgePath Pharmaceuticals (HPPI) and Tenax Therapeutics (TENX).
View all competitors.

What other stocks do shareholders of Pieris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Verastem (VSTM), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO), Allena Pharmaceuticals (ALNA) and Anavex Life Sciences (AVXL).

Who are Pieris Pharmaceuticals' key executives?

Pieris Pharmaceuticals' management team includes the following people:
  • Mr. Stephen S. Yoder, CEO, Pres & Director (Age 44, Pay $777.93k)
  • Dr. Hitto Kaufmann Ph.D., Sr. VP & Chief Scientific Officer (Age 49, Pay $361.33k)
  • Mr. Thomas Bures, VP of Fin. (Age 45)
  • Mr. Ahmed S. Mousa, Sr. VP of Corp. Operations, Gen. Counsel & Corp. Sec.
  • Maria Kelman, Director of Investor Relations
  • Mr. Frank Vollmering, VP of HR
  • Dr. Christine Rothe, Head of Discovery & Alliance Management and VP
  • Dr. Shane Olwill, Sr. VP & Head of Translational Science
  • Mr. Eckhard Niemeier, Sr. VP & Head of Bus. Devel.
  • Mr. Prompong Chaikul, Chief Supply Chain Officer (Age 33)

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.80%), Candriam Luxembourg S.C.A. (4.40%), Acadian Asset Management LLC (1.68%), Assenagon Asset Management S.A. (1.29%), Sigma Planning Corp (0.42%) and Wells Fargo & Company MN (0.37%). Company insiders that own Pieris Pharmaceuticals stock include Aquilo Capital Management, Llc and Bvf Partners L P/Il.
View institutional ownership trends for Pieris Pharmaceuticals.

Which institutional investors are selling Pieris Pharmaceuticals stock?

PIRS stock was sold by a variety of institutional investors in the last quarter, including Voss Capital LLC, AQR Capital Management LLC, Candriam Luxembourg S.C.A., BlackRock Inc., and Rock Creek Group LP.
View insider buying and selling activity for Pieris Pharmaceuticals.

Which institutional investors are buying Pieris Pharmaceuticals stock?

PIRS stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Acadian Asset Management LLC, Morgan Stanley, Caas Capital Management LP, Wells Fargo & Company MN, Sigma Planning Corp, Jane Street Group LLC, and Squarepoint Ops LLC.
View insider buying and selling activity for Pieris Pharmaceuticals.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $2.94.

How big of a company is Pieris Pharmaceuticals?

Pieris Pharmaceuticals has a market capitalization of $164.55 million and generates $46.28 million in revenue each year. The biotechnology company earns $-25,470,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Pieris Pharmaceuticals employs 114 workers across the globe.

What is Pieris Pharmaceuticals' official website?

The official website for Pieris Pharmaceuticals is www.pieris.com.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.